Form 8-K - Current report:
SEC Accession No. 0001159036-25-000020
Filing Date
2025-03-21
Accepted
2025-03-21 16:03:19
Documents
14
Period of Report
2025-03-17
Items
Item 5.02: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers

Document Format Files

Seq Description Document Type Size
1 8-K halo-20250317.htm   iXBRL 8-K 30382
5 GRAPHIC halo-20250317_g1.jpg GRAPHIC 15840
  Complete submission text file 0001159036-25-000020.txt   181751

Data Files

Seq Description Document Type Size
2 XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT halo-20250317.xsd EX-101.SCH 1798
3 XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT halo-20250317_lab.xml EX-101.LAB 21885
4 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT halo-20250317_pre.xml EX-101.PRE 12522
16 EXTRACTED XBRL INSTANCE DOCUMENT halo-20250317_htm.xml XML 2712
Mailing Address 12390 EL CAMINO REAL SAN DIEGO CA 92130
Business Address 12390 EL CAMINO REAL SAN DIEGO CA 92130 (858) 794-8889
HALOZYME THERAPEUTICS, INC. (Filer) CIK: 0001159036 (see all company filings)

EIN.: 880488686 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-32335 | Film No.: 25760404
SIC: 2836 Biological Products, (No Diagnostic Substances)
(CF Office: 03 Life Sciences)